Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2012

View Archived Issues

New S1P1 receptor agonists prepared by Allergan

Novel PI3K-alpha/mTORC1 inhibitors disclosed by Exelixis

Phase III study planned for MOD-4023

Novo Nordisk presents new long-acting drug for growth hormone deficiency

Lilly diabetes drug substantially decreases HbA1c without delaying recovery from hypoglycemia

Amicus reports preliminary results from phase II study in Pompe's disease

AstraZeneca patents novel agents for arrhythmia

Novel TRPV1 channel antagonists developed at GlaxoSmithKline

Polish team describes new fusion proteins for cancer

Korean researchers present novel protein kinase inhibitors

Merck KGaA designs new hPDK1 inhibitors

New fusion proteins for bone disorders designed in Korea

Research collaboration begins for Parkinson's disease gene therapy

EMA issues scientific opinion on Sanofi Pasteur vaccine

QRxPharma receives complete response letter for MoxDuo

Topica launches phase IIb/III study in onychomycosis

Dosing begins in first-in-human PA-401 trial

New gevokizumab trials initiated in uveitis and erosive osteoarthritis

FDA issues safety communication on cefepime

Depomed acquires rights to liquid-filled capsule analgesic

FDA approves first new weight loss drug in 13 years

Sunesis Pharmaceuticals receives milestone payment for kinase inhibitor program

PTC Therapeutics begins open-label ataluren study

FDA grants premarket approval to noninvasive test to detect prostate cancer

Janssen-Cilag applies for European approval of canagliflozin

CHMP issues opinion on Zyclara MAA

FDA issues complete response letter for Xarelto sNDA

Favorable preclinical profile supports clinical testing of grass pollen vaccine

Popular Stories

University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Beijing Innocare Pharma Tech discloses new GSPT1 degradation inducers
BioWorld Science
Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic...